Prometheus Biosciences Insiders
Prometheus Biosciences employs about 97 people. The company is managed by 10 executives with a total tenure of roughly 227 years, averaging almost 22.0 years of service per executive, having 9.7 employees per reported executive. Break down of Prometheus Biosciences' management performance can provide insight into the company performance.
Prometheus |
Prometheus Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.2006) % which means that it has lost $0.2006 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences' management efficiency ratios could be used to measure how well Prometheus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Prometheus Biosciences Workforce Comparison
Prometheus Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,491. Prometheus Biosciences claims roughly 97.0 in number of employees contributing just under 2% to equities under Health Care industry.
Prometheus Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prometheus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prometheus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Prometheus Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark McKenna over a year ago Disposition of 178098 shares by Mark McKenna of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Papa Joseph C over a year ago Acquisition by Papa Joseph C of 2278 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Marshall Keith W over a year ago Exercise or conversion by Marshall Keith W of 10000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 25000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Marshall Keith W over a year ago Exercise or conversion by Marshall Keith W of 10000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 700 shares of Prometheus Biosciences subject to Rule 16b-3 |
Prometheus Biosciences Notable Stakeholders
A Prometheus Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Prometheus Biosciences often face trade-offs trying to please all of them. Prometheus Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Prometheus Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Allison MD | Chief Officer | Profile | |
| Noel Kurdi | VP Communications | Profile | |
| Timothy Esq | G Sec | Profile | |
| Chris Doughty | Chief Officer | Profile | |
| Mark McKenna | CEO Pres | Profile | |
| Nori Ebersole | Chief Officer | Profile | |
| Olivier Laurent | Chief RD | Profile | |
| MBA MBA | Chief Officer | Profile | |
| Mark Stenhouse | Chief Officer | Profile |
Prometheus Biosciences Workforce Analysis
Traditionally, organizations such as Prometheus Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Prometheus Biosciences within its industry.Prometheus Biosciences Manpower Efficiency
Return on Prometheus Biosciences Manpower
| Revenue Per Employee | 70.2K | |
| Revenue Per Executive | 680.9K | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 14.2M | |
| Working Capital Per Employee | 7.1M | |
| Working Capital Per Executive | 68.5M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |